Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Brain Tumor
- Breast Cancer
- Colo-rectal Cancer
- CTLA4
- Liver Cancer
- Lung Cancer
- PD1
- Solid Tumor, Adult
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: TILs treatment of solid cancersMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 85 years
- Gender
- Both males and females
Description
Choose appropriate patients with advanced lung or other cancers, with written consent for this study; Perform biopsy or collect cancerous effusion in thorax or abdomen to obtain TILs by standard protocol; Grow TILs and engineered the tumor-effective TILs with CRISPRA-CAS9 technique to knockdown PD1 ...
Choose appropriate patients with advanced lung or other cancers, with written consent for this study; Perform biopsy or collect cancerous effusion in thorax or abdomen to obtain TILs by standard protocol; Grow TILs and engineered the tumor-effective TILs with CRISPRA-CAS9 technique to knockdown PD1 and electronic-transfection strategy to express scFvs that target PD1 and CTLA4; amplify the engineered T cells as needed, test the quality and killing activity of the TILs and then transfuse them back the patients via systemic or local injections via standard protocol, and follow up closely to collect related parameters as needed; To enhance the killing capability, tumor-noneffective TILs have also been genetically engineered to express various CARs targeting HER2/Mesothelin/Lewis-Y/PSCA/MUC1/ GPC3/AXL/EGFR/Claudin18.2/B7-H3/ROR1/GD2/AXL/Claudin6-DAP10 with knockdown of PD1/HPK1 as appropriate; Evaluate the clinical results as needed.
Tracking Information
- NCT #
- NCT04842812
- Collaborators
- Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
- Investigators
- Principal Investigator: Zhenfeng Zhang, MD, PhD Second Affiliated Hospital of Guangzhou Medical University
Get Well Soon